2022 gla180的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列各種有用的問答集和懶人包

設計和合成亞胺醣做為醣苷酶穩定劑用於治療溶小體儲積症

為了解決2022 gla180的問題，作者李皇毅 這樣論述：

Contents摘要 iAbstract iiContents iiiFigure Contents vTable Contents ixChapter 1. Introduction 11.1. Iminosugars: Naturally Occurring Polyhydroxylated Alkaloids 11.2. Iminosugars as Therapeutic Agents 41.3. Previous Works and Current Limitations 81.4. Motivation 14Chapte

r 2. Synthesis of (3S,4S,5S)-trihydroxylpiperidine derivatives as enzyme stabilizers to improve therapeutic enzyme activity in Fabry patient cell lines 172.1. Abstract 172.2. Background 182.3. Results and Discussion 212.4. Summary and Perspective 30Chapter 3. Identification of pH-depe

ndent binding profiles of pyrrolidine-based iminosugars for the stabilization of human α-galactosidase 313.1. Abstract 313.2. Background 333.3. Results and Discussion 393.4. Summary and Perspective 61Chapter 4. Unnatural polyhydroxylated pyrrolidines as acid alpha-glucosidase (GAA) st

abilizers: Enhancement of the enzyme activity for the treatment of Pompe disease 634.1. Abstract 634.2. Background 654.3. Results and Discussion 694.4. Summary and Perspective 80Chapter 5. Flexible synthesis of highly diverse polyhydroxylated piperidines through asymmetric organocatal

ytic aldol reaction 815.1. Background 815.2. Results and Discussion 885.3. Bioevaluation 975.4. Summary and Perspective 100Chapter 6. Conclusions 101Chapter 7. Experimental Section 1057.1. Chemical Synthesis 1067.2. Experimental Procedures 1397.3. Supplementary Information

150References 169Appendix 180 Figure ContentFigure 1.1. Structures of naturally occurring iminosugars isolated from plants 2Figure 1.2. Polyhydroxylated alkaloids binding toward sugar-processing enzymes 3Figure 1.3. Iminosugars as therapeutic agents for the treatment of carbohydrate-

mediated diseases 4Figure 1.4. Lysosomal storage diseases (LSDs) and their treatment 6Figure 1.5. The general strategy of natural product-inspired combinatorial chemistry (NPICC) and its applications 8Scheme 1.1. Synthesis of pyrrolidine-based iminosugars through five-membered chiral tri-O-

benzyl cyclic nitrones prepared from four D-pentoses. 10Scheme 1.2. Synthesis of pyrrolizidine- and indolizidine-based iminosugars 11Scheme 1.3. Synthesis of six-membered chiral cyclic nitrones 12Figure 1.6. A general strategy of developing diverse iminosugars as enzyme stabilizers for LSDs

14Scheme 1.4. The main topics of this dissertation 15Figure 2.1. Graphic abstract 17Figure 2.2. Examples of small molecules as stabilizers of therapeutic enzymes 19Scheme 2.1. Synthetic design of primary structures for potential scaffolds 20Scheme 2.2. Preparation of aminomethyl-(3S,

4S,5S)-trihydroxylpiperidines from cyclic nitrones 2-1 and 2-2 22Figure 2.3. Enzyme-based and cell-based characterization of piperidines 2-3‒2-6 23Figure 2.4. Preparation of the 24-membered primary library and their inhibition activity at 10 μM against rh-α-Gal A at pH 7.0 24Scheme 2.3. Syn

thesis of derivatives 2-15‒2-19 from nitrile 2-9 25Figure 2.5. Characterization of residual enzymatic activity of rh-α-Gal A in the presence of small molecules in FD cell lines 27Figure 2.6. Binding mode of 2-21 binding with rh-α-Gal obtained from docking computation 29Figure 3.1. Graphic a

bstract 32Figure 3.2. Iminosugars for the treatment of Fabry disease 35Scheme 3.1. Synthesis of C2-deprived, C-2 extended, C-2 hydroxymethylated pyrrolidines 41Scheme 3.2. Synthesis of C-2 aminomethylated pyrrolidines 42Figure 3.3. Evaluation of enzyme stabilizing activity of pyrrolidine

-based iminosugars 45Figure 3.4. Conformations of rh-α-Gal A bound ligands 48Figure 3.5. Thermodynamic and kinetic analysis of rh-α-Gal A with iminosugars 54Figure 3.6. Co-treatment of rh-α-Gal A and iminosugars in FD cells 56Figure 3.7. Enhancement effect of 3-5 toward rh-α-Gal A in Gla

KO mice. 60Figure 4.1. Graphic abstract 64Figure 4.2. Structures of small molecules as enzyme stabilizers (or PCs) 65Figure 4.3. Strategy for the development of new enzyme stabilizers for PD 68Figure 4.4. Structures of all unnatural ADMDP stereoisomers for initial screening, and thermal

shift study of all ADMDP stereoisomers toward rh-GAA 70Scheme 4.1. Preparation of Library I and Library II from 4-17 and 4-18, respectively 71Figure 4.5. Synthesis of 4-21 to 4-25 and evaluation of their enzyme stabilizing activity 72Figure 4.6. Characterization of residual enzymatic activ

ity by treating rh-GAA in the presence or absence of small molecules in PD cells. 78Figure 4.7. GAA activity in GAA KO mice 79Scheme 5.1. Current methods to prepare multi-substituted piperidine-based chiral cyclic nitrones 82Scheme 5.2. Current organocatalysts and asymmetric organocatalytic

aldol reaction 84Scheme 5.3. Preparation of piperidine-based iminosugars through asymmetric organocatalytic aldol reaction 85Scheme 5.4. Synthesis of C-3 amino piperidines from carbohydrate derivatives 86Scheme 5.5. A general strategy and synthetic design of diverse polyhydroxylated piperi

dines 87Scheme 5.6. Retrosynthetic analysis of C-3 amino DGJ and the derivatives 88Scheme 5.7. Initial attempt to prepare C3-typed building block 1. 89Scheme 5.8. Synthesis of C3-typed building block 1. 90Scheme 5.9. Synthesis of C4–typed building block 2. 91Scheme 5.10. Proposed mech

anism for a nucleophile attacking 5-40 with or without premixing Lewis acid (LA) 93Scheme 5.11. Proposed synthesis of building block 3 93Scheme 5.12. Synthesis of C-3 derived polyhydroxylated piperidines A and B 94Scheme 5.13. Proposed transition states (Houk-List model) for the proline-cat

alyzed aldol reaction 95Scheme 5.14. Synthesis of C-2 derived polyhydroxylated piperidine C and D 96Figure 5.1. Inhibitory activity of DGJ and 5-21 and the crystal structures of rh-α-Gal A bound to DGJ 97Figure 5.2. A general strategy for the design, synthesis, and biological evaluation of

iminosugars and the collaborators 99Figure 6.1. Summary of the synthetic strategies and results of this dissertation. 101Figure S2.1. Time-dependent inactivation of rh-α-Gal A in RPMI medium. 150Figure S2.2. Structures of 24-membered acid library. 150Figure S2.3. Stabilization of rh-α

-Gal A by 2-15‒2-19 evaluated in vitro by using heat inactivation. 151Figure. S2.4. Inhibition constant (Ki) of 2-21 at pH 7.0 and its inhibition mode determined by the Lineweaver–Burk plots 151Figure S3.1. Unfolding Tm of rh-α-Gal A 153Figure S3.2. A heat-induced denaturation assay. 15

4Figure S3.3. Complex crystal structures of rh-α-Gal A with 3-8 in the active site at pH 7.2. Fobs ‒ Fcalc density maps (blue mesh was contoured at 1.5 σ) 154Figure S3.4. The raw titration data of the power supplied to the system to maintain a constant temperature against time 156Figure S3.5.

pH-Dependence of 1/Ki for (a) 3-4 and (b) DGJ 157Figure S3.6. Titration curve of (a) 3-4 and (b) 3-5 158Figure S3.7. The predicted protonated states of dibasic iminosugar (a) 3-4 and (b) 3-5 binding to rh-α-Gal A 159Figure S3.8. pH-Dependent 1H-NMR spectra of 3-5 160Figure S4.1. Time-dep

endent inactivation of rh-GAA in DMEM medium 161Figure S4.2. Structures of acid library 162Figure S4.3. Thermal shift study of iminosugars (1 mM) toward rh-GAA 163Figure. S4.4. Inhibition constant (Ki) of 4-21, 4-23 and 4-24 at pH 4.6 and its inhibition mode determined by the Lineweaver–Bur

k plots. 163Figure S4.5. Complex structure of 4-23 (orange) binding with rh-GAA 165Figure. S4.7. Characterization of residual endogenous enzymatic activity in the presence of 4-21 in M519V PD fibroblast 165Figure. S4.7. Characterization of residual endogenous enzymatic activity in the prese

nce of 4-21 in M519V PD fibroblast 166Figure. S4.8. Characterization of residual enzymatic activity of rh-GAA in the presence of 4-21 and M6P (2 mM) in D645E PD fibroblast 166Figure S5.1. 1H-1H NOESY NMR spectra. 168 Table ContentsTable 5.1. Hexosaminidases associated diseases 86Table 5

.2. Diastereoselective nucleophilic addition of vinylMgBr to aldehyde 5-40 92Table S2.1. Inhibitory activity of alkaloids toward glycosidases at 100 μM 152Table S2.2. Cytotoxicity of alkaloids at 100 μM toward normal lymphocytes 152Table S4.1. Inhibitory activity against glycosidases at 0.1

mM 164Table S4.2. Cytotoxicity of 4-21 and 4-23 toward normal fibroblast 164